Treating Brain Tumors with Car-T Cells

Mon Feb 11, 2019
In this video, Bob Carter, MD, PhD, chief of Neurosurgery Service at Massachusetts General Hospital, discusses the promise of CAR-T therapy for solid tumors in the brain. Currently, no CAR-T cell therapy is approved for brain cancer by the FDA. His research, spanning 20 years, has been concentrated on developing CAR-T cells directed to a specific tumor antigen, called the EGFRB3 protein, that occurs in brain tumors is now in clinical trials. He anticipates that over the next several years, as his team continues to refine this therapy, that they will be able to offer this new immunotherapy developed in the labs of Mass General to patients with brain tumors. Read more here: in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital. Subscribe: